Business Wire

Arthur D. Little appoints Ulrica Sehlstedt to lead Global Healthcare & Life Sciences Practice

29.10.2019 12:38:00 EET | Business Wire | Press release

Share

Arthur D. Little (ADL) today announced the appointment of Dr. Ulrica Sehlstedt as the new Global Practice Leader for its Global Healthcare & Life Sciences (HCLS) Practice.

With over 20 years of experience in the healthcare and life sciences sectors, Ulrica is a Partner based in ADL’s Stockholm office. She joined the company 13 years ago and has worked extensively for ADL clients across the healthcare and life sciences ecosystem; covering global industry players (pharma, medtech and biotech companies), healthcare providers (public and private), early stage life sciences companies and investors in the sector. Prior to joining ADL, she was CEO of a biotech start-up in molecular diagnostics and also has an extensive background in academic research.

ADL’s Global HCLS Practice works side-by-side with its clients to meet their challenges as the sector goes through an era of enormous medical and technological innovation, while delivering results in a more resource-constrained ecosystem. It achieves this through deep industry knowledge, combined with creative thinking. This enables ADL to work with its clients in harnessing innovation to overcome their most difficult strategic challenges.

Ulrica will take over from Nils Bohlin, who has successfully led the Global HCLS Practice for 8 years, nearly quadrupling its size. After a successful career of 37 years with ADL, Nils has reached retirement age, but will stay in close contact with the company in a new role as Senior Advisor.

Ignacio García Alves, Chairman and Chief Executive Officer at Arthur D. Little comments: “The healthcare and life sciences ecosystem is changing rapidly as innovation and digitalization radically disrupt the sector. At ADL we have already built a strong position in the market, and Ulrica’s leadership will drive further growth in the Global Healthcare & Life Sciences Practice, thanks to her wide experience, deep understanding and commitment to innovation.”

Dr. Ulrica Sehlstedt, Global Practice Leader, Global Healthcare & Life Sciences Practice at Arthur D. Little adds: “While innovation has always been central to healthcare, we are seeing unprecedented change as advances accelerate across the sector. At the same time available resources have not kept pace, meaning that balancing innovation and outcomes requires strategic understanding and market knowledge. ADL’s Global Healthcare and Life Sciences Practice is already perfectly positioned to help our clients meet these challenges, and I look forward to leading the team as the industry transforms.”

Ulrica holds a PhD in biophysics from Stockholm University, as well as an MSc in Chemical Engineering from Chalmers University of Technology, Gothenburg, Sweden. She has also been a member of the Swedish Research Council’s Scientific Council for Medicine for six years, and is regularly engaged in expert roles for life science research and industry initiatives directed towards governments and policy makers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cate Bonthuys
Catalyst Comms
+44 7746 56773
cate@catalystcomms.co.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Collaborates with Chainguard to Strengthen Software Supply Chain Security through BlueVerse™ RightLogic6.8.2026 14:30:00 EEST | Press release

LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic collaboration with Chainguard, the trusted source for open source, to strengthen software supply chain security through BlueVerse™ RightLogic, LTM's cybersecurity assessment and risk assurance framework. The collaboration enables organizations to strengthen security while maintaining the speed and agility required for AI-enabled software development. With BlueVerse RightLogic, LTM combines AI-powered cyber risk assessment with a growing ecosystem of technology partners to help enterprises identify, assess, and remediate cyber exposure while accelerating AI adoption. Chainguard strengthens the BlueVerse RightLogic ecosystem by helping enterprises secure open-source components from the outset, complementing LTM's cybersecurity services to close the gap between AI-speed discovery and enterprise-speed remediation. As AI adoption accelerates, complex software supply chains and growing relian

teamLab Borderless in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries6.8.2026 14:07:00 EEST | Press release

teamLab Borderless: MORI Building DIGITAL ART MUSEUM (teamLab Borderless) in Tokyo has welcomed over 4 Million visitors as of July 31, 2026, approximately 2 years and 5 months since its opening.*1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806672709/en/ teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries These visitors arrived from more than 185 countries and regions. International visitors account for approximately 70% of the total number. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom and Germany. Among those who visited Japan between February 2024 and June 2026, approximately 1 in every 12 travelers from the United States, and 1 in every 9 travelers from Australia visited teamLab Borderless.*2 teamLab Borderless was selected by the U.S. based int

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 20266.8.2026 14:00:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under eva

Purina Named as First Publicly Announced NIQ ConnectAI Charter Client6.8.2026 13:45:00 EEST | Press release

NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today named Purina as the first publicly announced client in its ConnectAI Charter Program. The announcement follows NIQ’s launch of the program with five global organizations across personal care, pet care, beauty and beverages, with additional client announcements and case studies expected as engagements advance. Through ConnectAI, NIQ forward-deployed engineers and data scientists are working within Purina’s technology environment to explore how NIQ consumer and market intelligence can support everyday AI-enabled workstreams and help teams access relevant insights more efficiently. "Understanding the needs of pet owners requires a clear view of how consumer behaviors, shopping habits, and category trends are evolving,” said Brian Donovan, Strategy and Insights, Purina. “Purina is working with NIQ to explore how its trusted intelligence can be incorporated into Purina’s everyday, AI-enabled workstreams, helping our team

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin6.8.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial, titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression," or PIVOT, reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments. Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity. Compass will support the education and training of the investigators and their training team through the provision of training

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye